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Background. The aim of this prospective study was to determine whether a level of positive
airway pressure was generated in participants receiving nasal high ﬂow (NHF) delivered by the
OptiﬂowTM system (Fisher and Paykel Healthcare Ltd, Auckland, New Zealand) in a cardiothor-
acic and vascular intensive care unit (ICU).
Methods. Nasopharyngeal airway pressure was measured in 15 postoperative cardiac surgery
adult patients who received both NHF and standard facemask therapy at a ﬂow rate of 35 litre
min
21. Measurements were repeated in the open mouth and closed mouth positions. Mean
airway pressure was determined by averaging the pressures at the peak of inspiration of each
breath within a 1 min period, allowing the entire pressure proﬁle of each breath to be included
within the calculation.
Results. Low level positive pressure was demonstrated with NHF at 35 litre min
21 with
mouth closed when compared with a facemask. NHF generated a mean nasopharyngeal airway
pressure of mean (SD) 2.7 (1.04) cm H2O with the mouth closed. Airway pressure was signiﬁ-
cantly higher when breathing with mouth closed compared with mouth open (P0.0001).
Conclusions. This study demonstrated that a low level of positive pressure was generated with
NHF at 35 litre min
21 of gas ﬂow. This is consistent with results obtained in healthy volunteers.
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Patients with respiratory failure are typically treated with
three main respiratory support strategies, depending on the
severity of their illness. These are traditional oxygen
therapy, non-invasive ventilation, and invasive mechanical
ventilation.
1 A new respiratory support therapy has
recently been introduced into the adult arena. NHF allows
the delivery of up to 60 litre min
21 of heated and humidi-
ﬁed gas via a wide bore nasal cannula. However, the
effect of delivering such high-ﬂow rates into the nasophar-
ynx remains unclear.
In neonatal care, the delivery of relatively high ﬂows of
heated and humidiﬁed gas via a nasal cannula has gained
increasing acceptance in the treatment of respiratory con-
ditions.
2–4Studies of NHF in this patient population have
demonstrated an effect comparable with nasal continuous
positive airway pressure (CPAP).
4–6 In adults, there have
been reports that NHF may be beneﬁcial in the treatment
of obstructive sleep apnoea, attributable to a ﬂow-related
pressure effect.
7 There has been a similar pressure effect
reported in healthy adult volunteers
8–9 where a positive
relationship between ﬂow and airway pressure has also
been described. However, to date there have been no
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The aim of this study was to quantify the airway
pressure effect associated with NHF in an adult patient
cohort.
Methods
A prospective study was conducted in a 16-bed cardiothor-
acic and vascular ICU to test the hypothesis that a positive
airway pressure is generated. The study was approved by
the regional Ethics Committee. Written informed consent
was obtained from the participants before operation.
Participants who were undergoing elective cardiac
surgery were eligible for inclusion in this study. They
were excluded if they had a history of sinus problems,
nasal trauma, or a markedly deviated septum. In total, 20
participants were recruited, of which 15 completed the
study. Five participants were excluded before data collec-
tion: one participant was excluded from all study pro-
cedures as they returned from theatre in a critical
condition; one participant was excluded as it was not poss-
ible to insert the pressure measuring catheter; and three
were excluded after the pressure measuring catheter
became dislodged before data collection.
On return from theatre, while sedated and ventilated, a
10 F catheter was inserted into the nasopharynx via the
nose. The catheter was secured in place and remained in
situ overnight. Participants received all standard ICU care.
The morning after surgery, once awake and extubated,
participants were routinely mobilized to a chair and their
pain levels assessed. Analgesia was provided where
necessary, as per unit protocol, to ensure that each partici-
pant was able to breathe deeply and comfortably. For con-
sistency, all measurements were performed by one of the
researchers trained in this technique.
Before performing measurements, correct placement of
the catheter was conﬁrmed using end-tidal carbon dioxide
(CO2) monitoring. If necessary, the catheter was suctioned
and manipulated until a clear respiratory trace was
achieved. A visual check was also performed to locate the
tip of the catheter behind the uvula. The catheter was then
connected to the Honeywell precision pressure transducer
(PPT-0001 DWWW2VA-B, Honeywell International Ltd,
NJ, USA) using a laptop computer interface (Figs 1 and 2).
The OptiﬂowTM system (MR880 heated humidiﬁer, RT241
heated delivery tube, Fisher and Paykel Healthcare Ltd,
Auckland, New Zealand) with an air/oxygen blender (Bird
high-ﬂow blenders, Cardinal Healthcare, IL, USA) was
used for all measurements.
Once the system temperature stabilized (target; 378C
with an absolute humidity of 44 mg H2O litre
21), therapy
was commenced at 35 litre min
21 using the OptiﬂowTM
wide bore nasal cannula (Fig. 1; RT034 nasal cannula,
Fisher and Paykel Healthcare Ltd). As per the manufac-
turer’s recommendations, the investigators ensured that no
more than half the internal diameter of the nares was taken
up by the cannula. Participants were given 15 min on
the system to become accustomed to the feeling of
a
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Fig 1 OptiﬂowTM system set-up. a, OptiﬂowTM RT034 cannula; b, heater delivery tube RT241; c, MR880 heated humidiﬁer; d, laptop interface;
e, pressure transducer.
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887increased ﬂow and to allow breathing patterns to settle
before measurements were commenced. Measurements
were then repeated with a standard facemask (Fig. 2;
Medium Adult SEE-THRU
w Oxygen Mask, Hudson
Respiratory Care Inc., NC, USA) at 35 litre min
21 (target;
378C with an absolute humidity of 44 mg H2O litre
21)
connected by way of an adapter to the heated delivery
tube. This ensured that all equipment and conditions were
standardized with the exception of the interface. Oxygen
concentrations were titrated to meet participants’ require-
ments. Measurements were recorded with the participant’s
mouth open and mouth closed for each interface. Each
recording was taken over 1 min of quiet breathing.
A washout period of 5 min was allowed between each of
the measurements to ensure no carry-over effect between
therapies. During this time, the patency and position of the
catheter was re-checked.
At the end of the procedure, the nasopharyngeal catheter
was removed and the participant returned to their original
oxygen delivery device.
Nasopharyngeal pressure proﬁles were recorded for each
participant over 1 min. An example of one participant’s
trace is shown in Figure 3. Data analysis determined the
mean nasopharyngeal airway pressure. This required aver-
aging the pressure from the peak of inspiration of the ﬁrst
breath to the peak of inspiration of the last breath within a
1 min recording. This allowed the entire pressure proﬁle of
each breath within that 1 min period to be included in the
pressure calculation. All data analysis was performed
using Microsoft
w Ofﬁce Excel 2003. Data are presented as
mean (SD). Paired t-test was used to compare mean
differences between NHF and standard facemask, and
between the mouth open and mouth closed measurements
for each interface.
Results
Data from 15 participants were analysed. The participants
were 17 males and two females of mean (range) age 63
(41–79) yr, weight 86 (67–107) kg, and height 175 (156–
186) cm.
Signiﬁcantly higher nasopharyngeal airway pressures
were recorded with NHF in the mouth closed position
g
Fig 2 Standard facemask set-up. g, Mask adapter (commercially unavailable).
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Fig 3 Breathing pressure proﬁle of one participant over 1 min.
Nasopharyngeal pressure (cm H2O) generated at 35 litre min
21 using
NHF with the mouth closed (NHFMC) is shown in black.
Nasopharyngeal pressure (cm H2O) generated at 35 litre min
21 using a
facemask with the mouth closed (FMMC) is shown in grey.
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888when compared with mouth open [2.7 (1.04) vs 1.2 (0.76)
cm H2O( P¼0.001)] (Table 1). There was no signiﬁcant
difference in nasopharyngeal airway pressure generated
with facemask mouth open [0.11 (0.39) cm H2O] and
facemask mouth closed [0.2 (0.63) cm H2O] (P¼0.5). The
corresponding values of nasopharyngeal pressures with
NHF, during mouth open or mouth closed, were signiﬁ-
cantly higher than those with a facemask (P¼0.001).
Discussion
This study demonstrates that a signiﬁcant positive airway
pressure effect is delivered with NHF using the
OptiﬂowTM system and a wide bore nasal cannula. The
pressure effect was shown to be most evident with the par-
ticipant’s mouth closed, but was still signiﬁcant with the
mouth open, when compared with a facemask interface at
the same gas ﬂow rate.
The mean nasopharyngeal airway pressure rather than the
end-expiratory airway pressure was analysed. This was con-
sidered to be a more accurate assessment of overall therapy
effect. The terms CPAP and PEEP have been avoided as it
is not clear to us how these terms relate to NHF.
For the purposes of this study, a nasopharyngeal cath-
eter was used rather than an oesophageal balloon catheter,
due to the perceived patient risks and discomfort associ-
ated with the latter technique. Nasopharyngeal pressure
has been taken as the most feasible surrogate measure of
transpulmonary pressure. It should be noted that during
analysis, the pressure proﬁles from the ﬁrst four partici-
pants (Table 1) were noted to be dampened. Indeed, par-
ticipant number 3 had no analysable pressure traces. These
errors were assumed to be technique-related, but mean
data have been reported where possible. To assess for
difference, analysis was carried out including, and exclud-
ing, data belonging to the participants 1–4. Results
showed that the difference in treatment effect remained
similar whether these participants were included or not.
Previous research has shown comparable results with
those obtained in this study.
89
An overall effect on airway pressure was observed when
individual pressure proﬁles recorded in this study were
examined. As can be seen in Figure 3, the pressure tracing
recorded with a facemask tends to rotate around zero (atmos-
pheric pressure). With NHF, the entire pressure proﬁle of the
breath is elevated. Visual analysis of these proﬁles would
also seem to suggest that the expiratory phase is prolonged
when using NHF. This could be explained by the effect of
breathing out against the incoming gas ﬂow.
A large interpatient variability was observed in this
study. When participants using NHF breathed with mouth
closed, the mean nasopharyngeal pressure generated
ranged from 1.54 to 5.34 cm H2O (Table 1). We hypoth-
esize that this variability may be due to differences in leak
around the outside of the nasal cannula and the wide
variability in nare size among the study population.
A smaller leak may create an increased resistance to
expiration resulting in higher nasopharyngeal pressure.
Previous studies support this theory.
51 0Physiological
differences in airway anatomy may also explain some of
the variability. It is uncertain whether the presence of a
nasopharyngeal catheter to measure airway pressure as
used in this and other studies
89has an effect on the
pressure generated in the upper airway.
In spite of these limitations, it is evident that a positive
airway pressure is generated using NHF and this may have
important clinical implications. A number of clinical
beneﬁts are associated with conventional pressure-
generating devices, including improved oxygenation;
improved ventilation perfusion matching; reduced airways
resistance; reduced work of breathing; and the balancing
of intrinsic PEEP.
11 Studies to assess the extent to which
NHF is associated with these clinical beneﬁts are required.
In conclusion, NHF is a new respiratory support
modality into which little clinical research has been con-
ducted. We have shown that NHF can signiﬁcantly
increase mean nasopharyngeal airway pressure in an adult
patient population. This may be an important factor in
determining the most appropriate respiratory support
therapy for a particular patient.
Areas for future research would include the investi-
gation of airway pressure measurements at differing ﬂow
rates, clinical applications, and the inﬂuence of NHF on
patient outcomes.
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Table 1 Measurements from the 15 participants showing individual
nasopharyngeal pressures (cm H2O) and mean nasopharyngeal pressures (cm
H2O) with SD generated with NHF and facemask at 35 litre min
21 with the
open mouth (NHFMO and FMMO) and closed mouth positions (NHFMC and
FMMC)
Participant Mean nasopharyngeal pressure (cm H2O)
NHFMC NHFMO FMMC FMMO
1 1.7 1.6 1.3 0.3
2 2.7 1.7 — 1.3
3— — — —
4 1.5 0.9 20.2 20.5
5 1.6 0.2 20.01 0.02
6 2.2 0.5 0.005 20.01
7 3.4 2.1 0.02 0.06
8 2.7 1.6 20.003 0.04
9 3.4 0.7 20.09 0.02
10 2.2 0.9 0.02 20.04
11 5.3 2.3 1.7 0.4
12 1.7 0.1 20.5 0.02
13 2.5 2.4 0.6 20.06
14 3.0 0.7 0.006 0.04
15 3.7 1.5 20.1 0.03
Mean airway pressure at
35 litre min
21
2.7 1.2 0.2 0.1
SD 1.04 0.76 0.63 0.39
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